Merck & Co – known as MSD outside of the US and Canada – has announced that it will be expanding its respiratory diseases ...

According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of ...

Quantitative CT is becoming increasingly common for the characterisation of lung disease; however, its added potential as a clinical tool for predicting severe exacerbations remains understudied. We ...

Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...

Increasingly, research is pointing to the reality that while vapes do not contain the same dangerous chemicals as cigarettes, ...

A recent national study revealed ongoing symptom burden and communication gaps in COPD care, and provided physicians with actionable improvement strategies.

Background Chronic obstructive pulmonary disease (COPD) is a multicomponent condition that is characterised by airflow obstruction that is not fully reversible and is a major global cause of morbidity ...

Dietary approaches are shaping up as a key aspect of chronic obstructive pulmonary disease (COPD) management.

Chronic obstructive pulmonary disease (COPD) is a lung condition that often hides in plain sight. You may think you're ...

Many individuals with chronic obstructive pulmonary disease describe exacerbations in personal, varied terms, revealing a ...

The Business Research Company's Asthma and COPD Drugs Market 2025: Strategic Insights for Growth, Expansion, and Gaining Competitive Edge It will grow to $50.99 billion in 2029 at a compound annual ...